243 Users Online
Uterine Cancer Diagnostic Testing Market Segmented By Endometrial Carcinoma, Uterine Sarcoma Cancer Type by Abdominal Ultrasound Scanning, Transvaginal Ultrasound Scanning, Endometrial Biopsy, Hysteroscopy, Dilation and Curettage, Complete Blood Count, CA125 Marker Blood Test
Uterus a female organ also referred as the womb is located in the lower abdomen. It supports in the fetal development until birth. Uterine cancer is the malignant growth of cells comprised of uterine tissues. Uterine cancer is of two types, namely endometrial carcinoma and uterine sarcoma. Endometrial carcinoma generally occurs in the lining of the uterus, also called as the endometrium, whereas uterine sarcoma develops in the supporting network of the uterus such as tissues, bones and muscles associated with the uterus. The risk associated with the development of uterine cancer includes hyperplasia mostly in women who have never borne a child, obese women, and due to excessive intake of treatment drugs for breast cancer. Endometrial carcinoma is symptomatic in behavior and the major symptoms include abnormal bleeding from the vagina, pelvic pain or abrupt vaginal discharge. Unlike endometrial carcinoma, uterine sarcoma is asymptomatic in behavior and is diagnosed at later stages.
The uterine cancer diagnostic testing includes ultrasound scanning, biopsy procedures and blood tests. The ultrasound scanning tests use sound waves and generate images of the ovaries and the uterus. Two types of ultrasound scannings are involved with uterine cancer diagnostic testing, abdominal ultrasound scanning and transvaginal ultrasound scanning. The abdominal scanning test includes scanning of a filled bladder across the abdomen with the help of a small device called transducer, whereas in transvaginal scanning a transducer wand is inserted in the vagina to scan or create an image.
Biopsy procedures involve endometrial biopsy, hysteroscopy and dilation & curettage. Endometrial biopsy involves removal of some malignant tissues from the organ and sending it for a sampling procedure. In hysteroscopy, a small telescope like device is inserted through the vagina in the uterus to capture an image. Dilation & curettage is a conventional method which involves dilation of the cervix and insertion of a small microscope in the vagina. Endometrial biopsy and D&C is generally combined with a hysteroscopy procedure. Blood tests are done to assess general health and further for diagnosis of uterine cancer. Complete blood count is the first line of diagnosis because it helps to analyze the hormone level elevations. CA125 is a tumor marker blood test that specifically measures CA125 levels in the blood. CA125 is a glycoprotein and is also a tumor marker. The first line of diagnosis includes blood test and ultrasound scanning. Confirmatory tests include biopsy procedures.
In terms of revenue, the global uterine cancer diagnostic testing market is projected to expand at a CAGR of 7.8% during the forecast period and is expected to be valued at US$ 3,756.8 Mn by the end of 2026. Asia-Pacific market for uterine cancer diagnostic testing is expected to witness siginificant growth in the global uterine cancer diagnostic testing market over the forecast period.
The global uterine cancer diagnostic testing market is segmented into six major regions, namely North America, Latin America, Europe, Asia Pacific (Asia-Pacific excluding China), China and Middle East & Africa (MEA). In terms of value, North America market for uterine cancer diagnostic testing is expected to be the dominant regional market for uterine cancer diagnostic testing by 2018 end and is expected to expand at a CAGR of 5.7% over the forecast period.
Europe, Asia Pacific and China market for uterine cancer diagnostic testing are expected to be the fast-growing markets in terms of revenue in the global uterine cancer diagnostic testing market, registering CAGRs of 8.9%, 12.2% and 11.0%, respectively, over the forecast period.
In North America, the U.S. is expected to be the dominant market for uterine cancer diagnostic testing due to growing incidence of uterine cancer. According to the National Institutes of Health, the U.S. had a high incidence of uterine cancer becasuse of the growing obese population due to unhealthy lifestyles, and rise in the number of post-menopausal women population. Availability of cost-effective diagnosis and treatment options for uterine cancer diagnostic testing is also a factor expected to drive the growth of the market for uterine cancer diagnostic testing in the U.S. over the forecast period. Growing women geriatric population in the U.S. is also a major factor contributing to the growth of the uterine cancer diagnostic testing market.
According to the U.S. Census Bureau, in 2012, women aged 65 and above accounted for around 56.4% of total elderly population in the U.S. Besides, according to the 2017 world population statistics, in the window of women aged between 25 and 99 years, 52.9% women belonged to the age group of 50–99 years in the U.S. The U.S. has just shifted to the in-office physician services and at certain crux of this shift, there is a 237% increment in the in-office physician services for hysteroscopy and endometrial sampling, owing to the increase in reimbursements.
The second dominant market for uterine cancer diagnostic testing is China due to an increase in healthcare expenditure and funding by the government. The reimbursement policies by the government for women health screenings and treatment are also expected to drive the growth of the market for uterine cancer diagnostic testing in China. With a large population as well as growing post-menopausal women population demand for a higher scope of diagnosis. According to the data from the National Central Cancer Registry of China (NCCR), the mortality and incidence of cancer has been rapidly growing, where uterine cancer is the second most common type of gynecologic cancer in China.
The number of uterine cancer cases are also increasing in Europe, which is expected to drive the growth of the market for uterine cancer diagnostic testing in the region. According to the statistics provided by the European Society for Medical Oncology, approximately 7,400 new cases are registered in the U.K. and 88,068 in the European Union every year. Also, according to the Cancer Registry of Norway, in 20 gynecologic cancer cases, more than 1 is of endometrial cancer. Increase in healthcare expenditure is also expected to drive the growth of the Europe market for uterine cancer diagnostic testing over the forecast period.
|Diagnostic test type